Development of a novel ex vivo lung perfusion (EVLP) model in the rat as a mean to test gene therapy approaches in lung transplantation
Lung transplantation is the only effective, life-saving therapy for patients with end-stage lung diseases. However, organ shortage and post-transplant complications are important issues. Ex-vivo lung perfusion (EVLP) has emerged as a promising strategy in order to extend the donor pool, by reconditioning injured lungs. Additionally, EVLP may constitute a platform for administration of specific treatments to the lungs, such as gene therapy, avoiding side effects of a systemic exposure to therapeutic agents.
The aim of this study is to create a stable ex-vivo lung perfusion platform on a rat model and, subsequently, to use this platform for administration of viral vectors containing an immune-modulating gene. The efficacy of this treatment will be tested by observing the grade of rejection of treated lungs after allogenic transplantation.
S. Ferrari ci ha subito colpito nel suo ruolo di Assistente manager. L'estrema professionalità, la grande creatività e un sorriso entusiasmante, rendono S. Ferrari un elemento importante per tutto il team di LIFELAB - Living, Innovative, Fully Engineered,
Long-lasting and Advanced Bioreplacement.